Chipscreen Biosciences LTD
About Us
Chipscreen Biosciences (United States) LTD was established in New Jersey in April 2021. The parent company, Chipscreen Biosciences Shen Zhen, was Founded in March 2001 in China by a group of senior scientists returned from the United States, Chipscreen Biosciences focuses on developing innovative drugs with new mechanisms of action (MOA) for the treatment of human diseases in five major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals, so as to provide patients with affordable, efficacious drugs to meet their clinical needs.
Group Chairman and CEO
Dr. Lu Xianping, Founder, Chairman, and President. Dr. Lu graduated with a BSc in biochemistry from Sichuan University in 1983 and a Ph.D. in molecular biology from Peking Union Medical College, Chinese Academy of Medical Sciences in 1988. He pursued postdoctoral training at the University of California, San Diego (UCSD) in 1989 and co-founded Maxia Pharmaceuticals and Galderma Research Inc. in San Diego in 1994, serving as Director of Research at Galderma R&D. With more than 30 years of global experience in drug research, development, and management, Dr. Lu is highly accomplished in the fields of molecular medicine, oncology, neuroendocrinology, immunity, metabolism and skin diseases. He has published more than 100 articles in top international journals such as Science, Nature, and Lancet, and is named as the first inventor on over 100 invention patents in the field of drug discovery.
Working together to develop original drugs that benefit patients, we are all guided by the same dream and aspirations – making affordable innovative drugs for ordinary people.
Chiauranib
A highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.
This study is a Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Relapsed/Refractory Small Cell Lung Cancer.
Partnership Opportunities
Chipscreen Biosciences has a global intellectual property strategy, with patent portfolios in several countries and regions including the United States, Europe, Japan, South Korea, India, Australia, Russia, Brazil, Canada, Mexico, Indonesia, Egypt, Ukraine, and South Africa. Till now, Chipscreen has filed over 300 invention patents worldwide, with more than 100 of these granted. If you would like to partner with Chipscreen in any aspect, please use the Contact Us form to let us know.